Cancer-related anemia: Biological findings, clinical implications and impact on quality of life

Oncology

Volumn 68, Issue SUPPL. 1, 2005, Pages 12-21

  Blohmer, Jens Uwe ^a,j   Dunst, Jürgen ^b   Harrison, Louis ^c   Johnston, Patrick ^d   Khayat, David ^e   Ludwig, Heinz ^f   O'Brien, Mary ^g   Van Belle, Simon ^h   Vaupel, Peter ⁱ  

^a Sankt Gertrauden Hospital   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c BETH ISRAEL MEDICAL CENTER   (United States)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f WILHELMINEN HOSPITAL   (Austria)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^j Sankt Gertrauden Krankenhaus   (Germany)

more..

Author keywords

Anemia; Fatigue; Prognosis; Quality of life; Tumor hypoxia

Indexed keywords

ANTINEOPLASTIC AGENT;

ANEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; FATIGUE; GENOMICS; HEALTH SURVEY; HUMAN; HYPOXIA; PRIORITY JOURNAL; PROTEOMICS; QUALITY OF LIFE; TREATMENT OUTCOME; CELL HYPOXIA; IRON DEFICIENCY ANEMIA; METABOLISM; NEOPLASM; PROGNOSIS; PSYCHOLOGICAL ASPECT; REVIEW;

ANEMIA, HYPOCHROMIC; CELL HYPOXIA; DISEASE PROGRESSION; FATIGUE; HUMANS; NEOPLASMS; PROGNOSIS; QUALITY OF LIFE;

EID: 18344387984     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083129     Document Type: Conference Paper

References (65)

1. Fallowfield L, Gagnon D, Zagari M, et al: Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002;87:1341-1353.
2. Carelle N, Piotto E, Bellanger A, et al: Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002;95:155-163.
3. Cella D: Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25:43-46.
4. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
5. Caro JJ, Salas M, Ward A, et al: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-2221.
6. Moullet I, Salles G, Ketterer N, et al: Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998;9: 1109-1115.
7. Kern W, Schoch C, Haferlach T, et al: Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 2000;14:226-231.
8. Keating MJ, Smith TL, Lerner S, et al: Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma 2000;37:71-85.
9. Obermair A, Petru E, Windbichler G, et al: Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep 2000;7:639-644.
10. Sengelov L, Kamby C, Geertsen P, et al: Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol 2000; 46:357-364.
11. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-1626.
12. Ohlhauser C, Bulzebruck H, Ebert W, et al: Prognostic factors for survival in inoperable non-small-cell lung cancer: a multivariate regression analysis of 456 patients with radiation therapy. Onkologie 1997;20:126-131.
13. Waters JS, O'Brien ME, Ashley S: Management of anemia in patients receiving chemotherapy. J Clin Oncol 2002;20:601-603.
14. Münstedt K, Kovacic M, Zygmunt M, et al: Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol 2003;23:837-843.
15. Sevelda P, Gnant M, Lainz K: Influence of anemia on local relapse-free survival of premenopausal primary breast cancer patients under adjuvant CMF chemotherapy: and analysis of the Austrian Breast Cancer Study Group (abstract 257). Proc Am Soc Clin Oncol 2002;21: 65a.
16. Lee WR, Berkey B, Marcial V, et al: Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998;42:1069-1075.
17. Werner-Wasik M, Scott C, Cox JD, et al: Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000;48:1475-1482.
18. Kelleher DK, Matthiensen U, Thews O, et al: Tumor oxygenation in anemic rats: effects of erythropoietin treatment versus red blood cell transfusion. Acta Oncol 1995;34:379-384.
19. Kelleher DK, Mattheinsen U, Thews O, et al: Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 1996;56: 4728-4734.
20. Thews O, Koenig R, Kelleher DK, et al: Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998;78:752-756.
21. Thews O, Kelleher DK, Vaupel P: Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61:1358-1361.
22. Becker A, Stadler P, Lavey RS, et al: Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000;46: 459-466.
23. Vaupel P, Thews O, Mayer A, et al: Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol 2002;178:727-731.
24. Stuz̈ben G, Thews O, Pöttgen C, et al: Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001;127:346-350.
25. Mueller-Klieser W, Vaupel P, Manz R, et al: Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int J Radiat Oncol Biol Phys 1981;7:1397-1404.
26. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-6465.
27. Vaupel P, Kelleher DK, Höckel M: Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001;28:29-35.
28. Vaupel P, Thews O, Hoeckel M: Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001;18:243-259.
29. Höckel M, Vaupel P: Biological consequences of tumor hypoxia. Semin Oncol 2001;28:36-41.
30. Höckel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-276.
31. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
32. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-S67.
33. Henke M, Laszig R, Rübe C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
34. Leyland-Jones B: Reflection and reaction: breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
35. Van Belle SJ, Cocquyt V: Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003;47:1-11.
36. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
37. Graf W, Bergstrom R, Pahlman L, et al: Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur J Cancer 1994; 30A:453-457.
38. Grogan M, Thomas GM, Melamed I, et al: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-1536.
39. Glaser CM, Millesi W, Kornek GV, et al: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-715.
40. Rai KR, Sawitsky A, Cronkite EP, et al: Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
41. Binet JL, Auquier A, Dighiero G, et al: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
42. Durie BG, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.
43. Soni MK, Cella D: Quality of life and symptom measures in oncology: an overview. Am J Manag Care 2002;8:S560-S573.
44. World Health Organization: Constitution of the World Health Organization, Geneva, Switzerland, WHO Basic Documents, 1948.
45. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34:13-19.
46. Ludwig H, Strasser K: Symptomatology of anemia. Semin Oncol 2001;28:7-14.
47. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
48. Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
49. Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
50. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
51. Vogelzang NJ, Breitbart W, Cella D, et al: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34:4-12.
52. Stone P, Richardson A, Ream E, et al: Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000;11:971-975.
53. Dillon E, Kelly J: The status of cancer fatigue on the island of Ireland: AIFC Professional and Interim Patient Surveys. Oncologist 2003; 8(suppl 1):22-26.
54. Curt GA, Breitbart W, Cella D, et al: Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000;5:353-360.
55. Curt GA: Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000;37: 14-17.
56. Mock V, Atkinson A, Barsevick A, et al: NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Huntingt) 2000;14:151-161.
57. Cella D, Lai JS, Chang CH, et al: Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94:528-538.
58. Mercadante S, Gebbia V, Marrazzo A, et al: Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000;26:303-311.
59. Nowrousian MR: Pathophysiology of cancer-related anemia; in Nowrousian MR (ed): Recombinant Human Erythropoietin in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer, pp 13-34. New York, Springer Medicine, 2002.
60. Kurzrock R: The role of cytokines in cancer-related fatigue. Cancer 2001;92:1684-1688.
61. Stone P, Ream E, Richardson A, et al: Cancer-related fatigue - a difference of opinion? Results of a multicentre survey of healthcare professionals, patients and caregivers. Eur J Cancer Care (Engl) 2003;12:20-27.
62. Wang XS, Giralt SA, Mendoza TR, et al: Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:1319-1328.
63. Ludwig H, Birgegard G, Olmi P, et al: European Cancer Anaemia Survey (ECAS): prospective evaluation of anemia in over 15,000 cancer (CA) patients (pts) (abstract 623PD). Ann Oncol 2002;13(suppl 5):169.
64. Palumbo A, Falco P, Baldini L, et al: Correlation between fatigue and hemoglobin (Hb) level in multiple myeloma (MM) patients: results of a cross-sectional study (abstract 5096). Blood 2002;100:383b.
65. Shasha D, George MJ, Harrison LB: Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-1079.